Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Hitisha Patel"'
Autor:
Sunil Pancholi, Nikiana Simigdala, Ricardo Ribas, Eugene Schuster, Mariana Ferreira Leal, Joanna Nikitorowicz-Buniak, Camilla Rega, Teeru Bihani, Hitisha Patel, Stephen R. Johnston, Mitch Dowsett, Lesley-Ann Martin
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-15 (2022)
Abstract The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD elacestrant, versu
Externí odkaz:
https://doaj.org/article/acca486d20374dd3829e01221da2e13f
Autor:
Gregory R.J. Thatcher, Judy L. Bolton, Marton I. Siklos, Rui Xiong, Bradley T. Michalsen, Robert A. Scism, Emily N. Thayer, Yijin Wang, Shuai Wang, Sujeewa C. Piyankarage, Jaewoo Choi, R. Esala P. Chandrasena, Hitisha Patel, L.P. Madhubhani P. Hemachandra
The risk of developing hormone-dependent cancers with long-term exposure to estrogens is attributed both to proliferative, hormonal actions at the estrogen receptor (ER) and to chemical carcinogenesis elicited by genotoxic, oxidative estrogen metabol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c9bdf2f7a62eabcf8004690574fdef4
https://doi.org/10.1158/1940-6207.c.6544512
https://doi.org/10.1158/1940-6207.c.6544512
Autor:
Debra A. Tonetti, Gregory R.J. Thatcher, V. Craig Jordan, Philipp Y. Maximov, Huiping Zhao, Hitisha Patel, Rui Xiong, Bradley T. Michalsen, Teshome Gherezghiher, Bethany E. Perez White, Mary Ellen Molloy
Supplementary Figure 2: (A) Reconstructed ion chromatogram for the MRM transition m/z 241 to 208 of standard BTC (100ng/mL); (B) Reconstructed ion chromatogram for the MRM transition m/z 709 to 171 of standard DansylBTC (100ng/ml).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::553da67c96bd09e470eeffcb4947f81c
https://doi.org/10.1158/1535-7163.22501807.v1
https://doi.org/10.1158/1535-7163.22501807.v1
Autor:
Debra A. Tonetti, Gregory R.J. Thatcher, V. Craig Jordan, Philipp Y. Maximov, Huiping Zhao, Hitisha Patel, Rui Xiong, Bradley T. Michalsen, Teshome Gherezghiher, Bethany E. Perez White, Mary Ellen Molloy
Supplementary Figure 6: Plasma concentration-time profile of BTC following the administration of a single oral dose of 10 mg/Kg BTC to mice. Each data point represents the mean value {plus minus} SD (n = 3).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e44eaca976fbd326be9d8b22ce1549e1
https://doi.org/10.1158/1535-7163.22501795.v1
https://doi.org/10.1158/1535-7163.22501795.v1
Autor:
Gregory R.J. Thatcher, Judy L. Bolton, Marton I. Siklos, Rui Xiong, Bradley T. Michalsen, Robert A. Scism, Emily N. Thayer, Yijin Wang, Shuai Wang, Sujeewa C. Piyankarage, Jaewoo Choi, R. Esala P. Chandrasena, Hitisha Patel, L.P. Madhubhani P. Hemachandra
PDF file - 391K, Supplementary Figure S1: Recombinant COMT (10 microg/mL) was incubated with S-(5'-adenosyl)-L-methionine (500 nM) and raloxifene, DMA, or bazadoxifene (1 microM ) at 37 degrees C for 5 minutes prior to the addition of 6,7-dihydroxyco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fdad968c2164fd8129f4d51c4467a09
https://doi.org/10.1158/1940-6207.22524975.v1
https://doi.org/10.1158/1940-6207.22524975.v1
Autor:
Debra A. Tonetti, Gregory R.J. Thatcher, V. Craig Jordan, Philipp Y. Maximov, Huiping Zhao, Hitisha Patel, Rui Xiong, Bradley T. Michalsen, Teshome Gherezghiher, Bethany E. Perez White, Mary Ellen Molloy
Supplementary Figure 3: Reagents and conditions: (a) N-Bromoacetamide, DCM, EtOH, rt; (b) BBr3, dry DCM, 0sup>; (c) Dansyl chloride, TEA, DCM, 60 sup>C.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ee627368b0944458f58b75004103c50
https://doi.org/10.1158/1535-7163.22501804.v1
https://doi.org/10.1158/1535-7163.22501804.v1
Autor:
Debra A. Tonetti, Gregory R.J. Thatcher, V. Craig Jordan, Philipp Y. Maximov, Huiping Zhao, Hitisha Patel, Rui Xiong, Bradley T. Michalsen, Teshome Gherezghiher, Bethany E. Perez White, Mary Ellen Molloy
Supplementary Figure 4: The calibration standards were prepared by spiking working solution and IS (20ng/mL) into blank mouse plasma, giving final BTC concentrations of 5,10, 20, 30, 40, 50, and 100 ng/mL.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6134a2720a19720ca0dc869aea26b3f5
https://doi.org/10.1158/1535-7163.22501801.v1
https://doi.org/10.1158/1535-7163.22501801.v1
Autor:
Debra A. Tonetti, Gregory R.J. Thatcher, V. Craig Jordan, Philipp Y. Maximov, Huiping Zhao, Hitisha Patel, Rui Xiong, Bradley T. Michalsen, Teshome Gherezghiher, Bethany E. Perez White, Mary Ellen Molloy
Supplementary Figure 1: Western blot showing ERalpha expression in T47D:A18/neo, T47D:A18/PKCalpha, T47D:A18, T47D:A18-TAM1, MCF-7:WS8 and MCF-7 5C cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04fb5918be1e022be3c928f89ea7f82a
https://doi.org/10.1158/1535-7163.22501810
https://doi.org/10.1158/1535-7163.22501810
Autor:
Taronish D. Dubash, Aditya Bardia, Brian Chirn, Brittany A. Reeves, Joseph A. LiCausi, Risa Burr, Ben S. Wittner, Sumit Rai, Hitisha Patel, Teeru Bihani, Heike Arlt, Francois-Clement Bidard, Virginia G. Kaklamani, Philippe Aftimos, Javier Cortés, Simona Scartoni, Monica Binaschi, Nassir Habboubi, A. John Iafrate, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran
Publikováno v:
Cancer Research. 83:CT073-CT073
Purpose: Metastatic HR+ breast cancer initially responds to serial courses of endocrine therapy but ultimately becomes refractory Elacestrant, a new generation oral selective estrogen receptor degrader (SERD) and antagonist, has demonstrated efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30f236b3433ea38f9c7c50b77f27c49e
https://doi.org/10.1158/1538-7445.am2023-ct073
https://doi.org/10.1158/1538-7445.am2023-ct073
Autor:
Sunil Pancholi, Nikiana Simigdala, Ricardo Ribas, Eugene Schuster, Mariana Ferreira Leal, Joanna Nikitorowicz-Buniak, Camilla Rega, Teeru Bihani, Hitisha Patel, Stephen R. Johnston, Mitch Dowsett, Lesley-Ann Martin
Publikováno v:
NPJ breast cancer. 8(1)
The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD elacestrant, versus fulvest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5985109458dd5956ffa76240a536fe74
https://pubmed.ncbi.nlm.nih.gov/36446866
https://pubmed.ncbi.nlm.nih.gov/36446866